Research Reports | Market Assessment
June 2018

Hospital-Treated Gram-Positive Infections – Epidemiology – Mature Markets

All forecast data are available on the DRG Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.
DRG Epidemiology provides at least ten years of forecast data for the following hospital-treated infection patient populations:
Diagnosed HCAP events due to S. aureus.
Diagnosed BSI events due to CoNS.
Diagnosed BSI events due to S. aureus.
Diagnosed BSI events due to Enterococccus spp.
Diagnosed BSI events due to other gram-positive infections.
Diagnosed cIAI events due to S. aureus.
Diagnosed cIAI events due to CoNS.
… and many more (details available on request).
Note: Coverage may vary by country and region.
Source: DRG, part of Clarivate

Table of contents

  • Hospital-Treated Gram-Positive Infections - Epidemiology - Mature Markets
    • Introduction
      • Key Findings
        • Diagnosed Event Rate of UTIs per 1,000 per Year Among People of All Ages in 2021 and 2031
        • Relative Sizes of the Factors Contributing to the Trend in Diagnosed Events of UTIs over the Next Ten Yearsttttttttt
        • Number of Additional Diagnosed Events of UTIs Incurred Over the Period 2021-2031 Across the Countries Under Study Due to Trends in Risk
      • Epidemiology Data
      • Methods
        • Diagnosed Urinary Tract Infection Events
        • Diagnosed Bloodstream Infection Events
        • Diagnosed Nosocomial Pneumonia Events
        • Diagnosed Complicated Intra-Abdominal Infection Events
        • Diagnosed Surgical-Site Infection Events
        • Diagnosed Complicated Skin and Skin Structure Events
        • UTI Pathogen Distribution
        • NP Pathogen Distribution
        • BSI Pathogen Distribution
        • cIAI Pathogen Distribution
        • SSI and cSSSI Pathogen Distribution
      • Reference Materials
        • Literature Review
          • Studies Included in the Analysis of Hospital-Treated Gram-Positive Infections
          • Studies Excluded in the Analysis of Hospital-Treated Gram-Positive Infections
        • Risk/Protective Factors
          • Risk/Protective Factors for Hospital-Treated Gram-Positive Infections
        • Abbreviations
        • Bibliography
        • Glossary
    Mariah Scott
    Mariah Scott

    Mariah J. Scott, M.S., M.P.H., is an associate epidemiologist at Clarivate. Previously, she investigated patient-reported outcomes on health-related quality of life during the transition from pediatric to adult care in patients with Sickle Cell Disease throughout the state of New Jersey. Ms. Scott received her B.S. in Molecular Biology from Montclair State University and her M.S. from Seton Hall University where she studied Microbiology and Immunology. She also holds an M.P.H. degree in epidemiology from Rutgers University.

    T.J. Arndt, M.P.H., C.P.H.
    T.J. Arndt, M.P.H., C.P.H.

    Thomas J. Arndt, M.P.H., C.P.H., is a senior epidemiologist at Clarivate. He earned his master’s degree in public health at the University of Florida, where he conducted an internship developing a clinical model for noninvasively screening for nonalcoholic steatohepatitis (NASH). He also holds a B.S. in microbiology and cell science and a B.A. in Spanish, both from the University of Florida. While studying at the University of Florida, Mr. Arndt worked in two physiology-based research labs focusing on maternal and fetal stresses during pregnancy and parturition.

     

    Login to access report
    Back to all Market Assessment reports
    Login to access report

    launch Related Market Assessment Reports